INTRODUCTION
Dairy intake has been consistently associated with increased risk of prostate cancer in many epidemiologic studies conducted during the past two decades. The anticarcinogenic properties of vitamin D have been studied in the laboratory for many years, and 1,25 dihydroxyvitamin D 3 (1,25 D) , the most potent vitamin D metabolite, has consistently been shown to inhibit prostate cancer cell growth and development. Recently, it has been reported that calcium, and specifically dairy calcium, may increase the risk of prostate cancer. 1,25 D regulates calcium metabolism in the body, and, consequently, dietary calcium intake can suppress circulating 1,25 D levels. Thus, a hypothesis has emerged combining these different areas of research suggesting that calcium, particularly from dairy products, may elevate prostate cancer risk by reducing circulating 1,25 D. This hypothesis does not exclude, however, that calcium and 1,25 D may exert other independent effects on prostate cancer development. The following review will briefly summarize the large body of evidence on dairy intake and prostate cancer, which sets a background for the current studies on calcium. We will then address more specifically the experimental and epidemiologic research on vitamin D and prostate cancer and the recent epidemiologic studies on calcium intake and prostate cancer risk.
DAIRY PRODUCTS AND RISK OF PROSTATE CANCER
Seven (1-7) of 14 case-control (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) , and five (15) (16) (17) (18) (19) of nine cohort (15) (16) (17) (18) (19) (20) (21) (22) (23) studies have reported statistically significant positive associations between some aspect of dairy intake and prostate cancer risk (table 1) . Overall, 12 (1-12) of the 14 case-control studies (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) and seven (15-19, 21, 23) of the nine cohort studies (15-23) observed a positive association for some measure of dairy products and prostate cancer; this is one of the most consistent dietary predictors for prostate cancer in the published literature. In these studies, men with the highest dairy intakes had approximately double the risk of total prostate cancer, and up to a fourfold increase in risk of metastatic or fatal prostate cancer relative to low consumers (17, 24) . It remains unknown which compounds in dairy products might be responsible for this association; however, several recent studies which have been able to investigate nutrients more thoroughly suggest that calcium, and perhaps phosphorous, may play important roles.
Originally, it was speculated that the fat content in milk may affect risk of prostate cancer. However, a few of the more recent studies with comprehensive dietary assessments present evidence to the contrary. In the Health Professionals Follow-up Study and a large Swedish case-control study, the association for dairy foods was independent of fat intake, as well as several other measured risk factors (6, 17) . Most recently, in the Physicians' Health Study, fat and protein from dairy products were not risk factors for prostate cancer, and in the Health Professionals Follow-up Study and Physicians' Health Study, skim and low-fat milk were positively associated with prostate cancer risk (17, 19) . Higher low-fat milk intake has been linked to higher levels of circulating insulin-like growth factor 1 (25) , and plasma insulin-like growth factor 1 has been positively associated with elevated prostate cancer risk (26) (27) (28) . Thus, the positive association between dairy/milk intake and prostate cancer risk may be partially due to increased levels of insulin-like growth factor 1; this hypothesis is speculative and requires further study.
A few studies also suggest that the association between dairy products and prostate cancer may be particularly strong among older men and for advanced or fatal prostate cancer (6, 17) . This indicates a potential role for dairy products in the progression as well as the incidence of prostate cancer.
VITAMIN D AND PROSTATE CANCER
In 1990, Schwartz and Hulka (29) hypothesized that vitamin D deficiency may be related to risk of prostate cancer. They made the observation that black race, northern latitudes, and older age all appeared to be positively correlated with greater risk of prostate cancer as well as vitamin D deficiency. They suggested that lower levels of pre-vitamin D, which we receive from sunlight exposure, and 25 hydroxyvitamin D, which is produced in the liver through hydroxylation of pre-vitamin D, could influence production of 1,25 D (29). 1,25 D is produced by means of hydroxylation of 25 hydroxyvitamin D in the kidneys, is the most active vitamin D metabolite, is important for normal cal- Ewings and Bowie (14) Deneo-Pellegrini et al. (13) Hayes et al. (11) Jain et al. (7) Tzonou et al. (12) Snowdon et al. (21) Mills et al. (20 Subsequent to these reports, however, three other studies on serum 1,25 D and risk of prostate cancer have been mostly null. Braun et al. (45) found no association, although there were only 61 cases in this report. In a study among Japanese-American men in Hawaii, Nomura et al. (46) found no evidence of association; however, the men in this study had markedly higher levels of vitamin D metabolites than those reported in other studies. This is likely due to the greater sun exposure men receive in Hawaii and might have influenced the ability to detect any association. Gann et al. (47) did not observe any association in the Physicians' Health Study, except a suggestion of reduced risk (not statistically significant) among the sub-group of men who also had high 25 hydroxyvitamin D levels. Thus, while there is a growing body of evidence that 1,25 D plays a role in prostate cancer initiation, promotion, and progression, the few studies conducted among humans using single serum (50) also observed no association for TaqI, but unlike the Japanese study, there was no overall association between polymorphisms in Bsml and risk of prostate cancer. However, among men with plasma 25 hydroxyvitamin D levels below the median, those who were BB versus bb in the Bsml gene had a statistically significant 57 percent reduction in risk of prostate cancer. This relation was stronger among the older men (relative risk = 0.18; 95 percent confidence interval: 0.05, 0.68); p value for interaction < 0.01). There was also some suggestion of an interaction between 1,25 D levels and this gene, although the p value was not statistically significant (p = 0.15). The functional consequences, if any, of the various VDR polymorphisms have yet to be elucidated, and further study is warranted.
Overall, there is reasonable evidence supporting a role for vitamin D, its metabolites, and its receptor in the development and progression of prostate cancer. Further experimental and epidemiologic research is recommended, including studies focused on potential gene-environment interactions.
CALCIUM AND PROSTATE CANCER
Recently, another approach to examining the vitamin D hypothesis has been to study dietary factors that regulate 1,25 D levels in humans, mainly calcium and phosphorous. When serum levels of calcium are low, 1,25 D acts on the bones, kidneys, and intestines to increase retention and absorption of calcium until serum levels return to a normal range (30) . Similarly, if serum levels of calcium are high, production of 1,25 D is suppressed by reduced parathyroid hormone production. The physiologic link between serum calcium levels and 1,25 D is well established (30) , and more recently, epidemiologic studies have observed a small but statistically significant inverse correlation between selfreported dietary intakes of calcium and serum levels of 1,25 D (r = approximately -0.15; p < 0.05) (19, 23) . Dietary phosphorous can increase as well as decrease 1,25 D levels, depending on serum calcium and phosphorous status. Dietary vitamin D does not correlate with 1,25 D because the latter is tightly regulated and primarily responsible for serum calcium and phosphorous homeostasis.
Relatively few epidemiologic studies have recently examined calcium and phosphorous intake and risk of prostate cancer (table 2) . One cohort (18) and three case-control (11, 52, 53) studies have reported null associations for calcium intake and prostate cancer risk, and one case-control study from Serbia observed a statistically significant inverse association (54). Two cohort studies (17, 19) and one large case-control study (6) reported moderate to strong positive associations; two other prospective and case-control studies reported suggestive positive associations, however, the trends were not significant (12, 23) .
The strongest evidence for an association between calcium intake and risk of prostate cancer comes from the Health Professionals Follow-up Study, which had a comprehensive dietary assessment of calcium from food as well as multivitamins, calcium supplements, and other sources (e.g., antacids-TUMS® (SmithKline Beecham, Pittsburgh, Pennsylvania)) (17) . In this study, men who consumed more than 2,000 mg of calcium daily had a multivariate relative risk of 4.6 (95 percent confidence interval: 1.9, 11.1) for metastatic and fatal prostate cancer compared with men consuming less than 500 mg of calcium daily. This association was independent of age, body mass index, total energy intake, fat, fructose, phosphorous, vitamin D, vitamin E, and lycopene intake. Independent associations were observed for calcium from supplements only and calcium from foods. Kristal et al. (53) also examined the effect of specific calcium supplements in a large case-control study (n = 697), but observed no relation to prostate cancer risk. However, in this study the authors over-selected younger men with stage A or stage B disease (75 percent). Less than 10 percent of the cases and controls reported usage of calcium supplements, and the authors collected information only on frequency of supplement use rather than actual amounts of supplemental calcium Chan et al. (6) Hayes et al. (11) Tzonou et al. (12) Kristal et al. (53) Giovannucci et al. (17) Shuurman et al. (18) Chan et al. (23) Chanet al. (19) taken daily. Such differences in study design between this case-control study and the Health Professionals Follow-up Study (which consisted of an older population with more advanced disease and detailed assessment of milligrams of calcium intake from food and various supplemental sources) may partially explain discrepancies in the results. In a more recent investigation of the Physicians' Health Study, dairy intake, and specifically calcium from dairy products, was linked to greater risk of prostate cancer (19) . Although this study did not have complete dietary assessment, we were able to demonstrate that calcium from dairy products, rather than fat or protein from dairy products, was positively associated with prostate cancer risk. Additionally, skim milk calcium appeared to be the single dairy item linked to prostate cancer as well as to lower levels of 1,25 D (whole milk, cheese, and ice cream, or calcium from these sources, were not associated with prostate cancer risk when examined individually). One cannot exclude the possibility that this was due to chance, or that perhaps skim milk was assessed with the least measurement error.
In three of the studies on calcium intake (6, 17, 23) , consideration of phosphorous intake in the multivariate models appeared to enhance the association between calcium and prostate cancer risk. Additionally, there were suggestive inverse associations for phosphorous intake; however, the results were not consistently statistically significant (6, 17, 23) . In the observational cohort of the Alpha-Tocopherol Beta-Carotene Cancer Prevention Trial, there was a borderline significant interaction between calcium and phosphorous intake and risk of prostate cancer (p = 0.09) (23) . Phosphorous influences 1,25 D levels differently at the two extremes. Extremely low levels of circulating phosphate leads to increased 1,25 D production while very high intakes of phosphorous (double normal intake) tend to lower serum 1,25 D levels (55). Phosphorous can also bind to calcium in the intestine, decreasing bioavailability of calcium, which may lead to higher circulating 1,25 D levels. Thus, future studies on calcium and 1,25 D and risk of prostate cancer should also consider phosphorous intake.
CONCLUSION
In summary, there is reasonable evidence that both vitamin D metabolites and calcium, and specifically calcium from dairy sources, play important roles in the development of prostate cancer. Given current national enthusiasm to increase calcium consumption in efforts to prevent other chronic diseases (e.g., osteoporosis), further study of these factors is warranted, particularly in aging men. Additional studies that assess serum vitamin D metabolites, vitamin D binding proteins, VDR polymorphisms, dietary and supplemental calcium intakes, and phosphorous intake are recommended.
